+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 119 Pages
  • April 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5589946
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

According to the recently published report 'Exportin 1 - Drugs In Development, 2022'; Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies.

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active Ran-GTP. Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli.

The report 'Exportin 1 - Drugs In Development, 2022' outlays comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 2 and 2 respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Genetic Disorders, Infectious Disease and Metabolic Disorders which include indications Diffuse Large B-Cell Lymphoma, Solid Tumor, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Colorectal Cancer, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Endometrial Cancer, Liposarcoma, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myelofibrosis, Natural Killer Cell Lymphomas, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma, Amyloidosis, Amyotrophic Lateral Sclerosis, Anaplastic Astrocytoma, B-Cell Non-Hodgkin Lymphoma, Bone Sarcoma, Breast Cancer, Burkitt Lymphoma, Cervical Cancer, Chondrosarcoma, Coronavirus Disease 2019 (COVID-19), Cytomegalovirus (HHV-5) Infections, Dedifferentiated Liposarcoma, Duchenne Muscular Dystrophy, Epstein-Barr Virus (HHV-4) Infections, Ewing Sarcoma, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Fallopian Tube Cancer, Follicular Lymphoma, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Tumor, Hematological Tumor, Hepatocellular Carcinoma, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leiomyosarcoma, Malignant Mesothelioma, Mantle Cell Lymphoma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Sclerosis, Nasopharyngeal Cancer, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Ovarian Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Post-Transplant Lymphoproliferative Disorder, Primary Mediastinal B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Respiratory Syncytial Virus (RSV) Infections, Rheumatoid Arthritis, Small-Cell Lung Cancer, Spinal Cord Injury, Synovial Sarcoma, Thymoma (Thymic Epithelial Tumor), Traumatic Brain Injury, Unspecified Influenza Virus Infections, Urinary Tract Cancer and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The report provides a snapshot of the global therapeutic landscape for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)
  • The report reviews Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics

Reasons to Buy


  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

IntroductionReport CoverageExportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Overview
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Companies Involved in Therapeutics DevelopmentExportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Drug ProfilesExportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Dormant ProductsExportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Discontinued ProductsExportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Product Development Milestones
Featured News & Press Releases
  • Apr 06, 2022: Antengene's pivotal "MARCH" study to evaluate selinexor (ATG-010) in relapsed or refractory multiple myeloma published in BMC Medicine
  • Mar 29, 2022: Antengene announces IND approval in China for a phase II study of Eltanexor (ATG-016) in patients with High-Risk Myelodysplastic Syndrome
  • Mar 16, 2022: Karyopharm announces upcoming presentations of phase 3 SIENDO study of selinexor in patients with advanced or recurrent endometrial cancer
  • Mar 09, 2022: Antengene announces XPOVIO approved by the TGA in Australia for the treatment of relapsed and/or refractory multiple myeloma and triple class-refractory multiple myeloma
  • Mar 01, 2022: Antengene announces XPOVIO regulatory approval in Singapore for the treatment of relapsed and/or refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma in three indications
  • Mar 01, 2022: Karyopharm provides U.S. regulatory update on Selinexor in advanced or recurrent Endometrial Cancer
  • Feb 08, 2022: Karyopharm announces Phase 3 SIENDO study meets primary endpoint with statistically significant increase in progression-free survival in patients with advanced or recurrent endometrial cancer
  • Jan 24, 2022: Karyopharm receives orphan drug designation from FDA for eltanexor for the treatment of myelodysplastic syndromes
  • Dec 29, 2021: Antengene announces first patient dosed in REACH study of ATG-016 for the treatment of advanced solid tumors
  • Dec 18, 2021: Antengene announces NDA approval by NMPA for XPOVIO, China's first XPO1 inhibitor, for the treatment of adults with relapsed or refractory multiple myeloma
  • Dec 14, 2021: Antengene presents results of phase 1b TOUCH trial of Selinexor for the treatment of T and NK-Cell lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting
  • Dec 11, 2021: Karyopharm announces presentation of updated phase 2 selinexor data in patients with myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition
  • Dec 06, 2021: Karyopharm announces dosing of first patient in a new phase 2 study evaluating single-agent selinexor versus physician's choice in previously treated myelofibrosis
  • Dec 02, 2021: Karyopharm completes patient recruitment in phase 3 SIENDO study of selinexor in patients with endometrial cancer
  • Nov 18, 2021: Antengene announces IND approval in China for a phase I/II Study of Selinexor (ATG-010) in patients with non-Hodgkin lymphoma
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
List of Tables
  • Number of Products under Development by Stage of Development, 2022
  • Number of Products under Development by Therapy Areas, 2022
  • Number of Products under Development by Indications, 2022
  • Number of Products under Development by Companies, 2022
  • Products under Development by Companies, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Pipeline by Biogen Inc, 2022
  • Pipeline by CanBas Co Ltd, 2022
  • Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022
  • Pipeline by Karyopharm Therapeutics Inc, 2022
  • Pipeline by Oita University Institute of Advanced Medicine Inc, 2022
  • Pipeline by Wigen Biomedicine Technology (Shanghai) Co Ltd, 2022
  • Dormant Products, 2022
  • Discontinued Products, 2022

List of Figures
  • Number of Products under Development by Stage of Development, 2022
  • Number of Products under Development by Therapy Areas, 2022
  • Number of Products under Development by Top 10 Indications, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Biogen Inc
  • CanBas Co Ltd
  • Jiangsu Carephar Pharmaceutical Co Ltd
  • Karyopharm Therapeutics Inc
  • Oita University Institute of Advanced Medicine Inc
  • Wigen Biomedicine Technology (Shanghai) Co Ltd